GLP-1s

Between 2019 and 2024, the use of GLP-1 drugs to treat overweight or obesity increased nearly 587%. Originally developed to treat diabetes, GLP-1s such as Ozempic and Mounjaro later gave rise to obesity-only focused counterparts, including Wegovy (approved in 2021) and Zepbound (approved in 2023). As of this writing, about 1 in 8 adults (12%) say they’ve taken a GLP-1 drug, even while data about their long-term use remains limited — particularly concerning weight loss. 

MedShadow is committed to covering new iterations of these drugs, as well as emerging research and potential side effects. Stories in this series were accurate and complete at the time of publication.

Are you, or have you ever been, on a GLP-1 and have a story to share? Email Jessica@medshadow.org